[go: up one dir, main page]

BRPI0920984A2 - Método para reduzir trombocitopenia e trombocitopenia associada à mortalidade. - Google Patents

Método para reduzir trombocitopenia e trombocitopenia associada à mortalidade.

Info

Publication number
BRPI0920984A2
BRPI0920984A2 BRPI0920984A BRPI0920984A BRPI0920984A2 BR PI0920984 A2 BRPI0920984 A2 BR PI0920984A2 BR PI0920984 A BRPI0920984 A BR PI0920984A BR PI0920984 A BRPI0920984 A BR PI0920984A BR PI0920984 A2 BRPI0920984 A2 BR PI0920984A2
Authority
BR
Brazil
Prior art keywords
thrombocytopenia
mortality
reduce
risk
reducing
Prior art date
Application number
BRPI0920984A
Other languages
English (en)
Inventor
Valgimigli Marco
Original Assignee
Iroko Cardio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42198725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920984(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iroko Cardio Llc filed Critical Iroko Cardio Llc
Publication of BRPI0920984A2 publication Critical patent/BRPI0920984A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MÉTODO PARA REDUZIR TROMBOCITOPENIA E TROMBOCITOPENIA ASSOCIADA À MORTALIDADE. A presente invenção refere-se a métodos para reduzir o risco de mortalidade e morbidez associadas à trombocitopenia, e para reduzir o risco de se tornar trombocitopênico, em pacientes cujo tratamento requer inibição de agregação de plaquetas. Os métodos envolvem a administração de um sal de tirofiban farmaceuticamente aceitável.
BRPI0920984A 2008-11-21 2009-11-20 Método para reduzir trombocitopenia e trombocitopenia associada à mortalidade. BRPI0920984A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11697608P 2008-11-21 2008-11-21
PCT/US2009/006240 WO2010059244A2 (en) 2008-11-21 2009-11-20 Method for reducing thrombocytopenia and thrombocytopenia-associated mortality

Publications (1)

Publication Number Publication Date
BRPI0920984A2 true BRPI0920984A2 (pt) 2017-07-11

Family

ID=42198725

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920984A BRPI0920984A2 (pt) 2008-11-21 2009-11-20 Método para reduzir trombocitopenia e trombocitopenia associada à mortalidade.

Country Status (18)

Country Link
US (1) US20120059036A1 (pt)
EP (1) EP2355824A4 (pt)
KR (1) KR20110108330A (pt)
AU (1) AU2009318101A1 (pt)
BR (1) BRPI0920984A2 (pt)
CL (1) CL2011001175A1 (pt)
CO (1) CO6390039A2 (pt)
CR (1) CR20110271A (pt)
DO (1) DOP2011000149A (pt)
EC (1) ECSP11011152A (pt)
MA (1) MA32820B1 (pt)
MX (1) MX2011005376A (pt)
NI (1) NI201100101A (pt)
PE (1) PE20110946A1 (pt)
SV (1) SV2011003915A (pt)
TN (1) TN2011000256A1 (pt)
WO (1) WO2010059244A2 (pt)
ZA (1) ZA201103741B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101996880B1 (ko) 2018-03-16 2019-07-05 경성대학교 산학협력단 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물
CN112441962A (zh) * 2019-09-04 2021-03-05 武汉武药科技有限公司 替罗非班及其纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
KR20080067717A (ko) * 2001-01-26 2008-07-21 쉐링 코포레이션 스테롤 흡수 억제제와 혈액 조절제를 포함하는 혈관 질환의치료 또는 예방용 약제학적 조성물
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
SI1400245T1 (sl) * 2002-09-09 2006-10-31 Trigen Ltd Soli boronske kisline, uporabne v parenteralnih formulacijah za selektivno inhibiranje trombina
ES2340179T3 (es) * 2004-05-12 2010-05-31 Bristol-Myers Squibb Company Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
KR20070091607A (ko) * 2004-10-12 2007-09-11 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 설폰아미드 주변 치환된바이사이클릭 화합물

Also Published As

Publication number Publication date
AU2009318101A1 (en) 2010-05-27
MA32820B1 (fr) 2011-11-01
CL2011001175A1 (es) 2011-11-11
WO2010059244A3 (en) 2010-10-14
NI201100101A (es) 2011-12-19
EP2355824A2 (en) 2011-08-17
CO6390039A2 (es) 2012-02-29
ZA201103741B (en) 2012-01-25
MX2011005376A (es) 2011-10-19
KR20110108330A (ko) 2011-10-05
WO2010059244A2 (en) 2010-05-27
PE20110946A1 (es) 2012-01-05
SV2011003915A (es) 2011-07-01
DOP2011000149A (es) 2011-10-31
TN2011000256A1 (en) 2012-12-17
EP2355824A4 (en) 2012-11-07
US20120059036A1 (en) 2012-03-08
CR20110271A (es) 2011-10-13
ECSP11011152A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
MX2015014512A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
BR112013033051A2 (pt) roda dentada com endentação inclinada e segmento para uma roda dentada
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
BR112015021480A2 (pt) soluções de hidromorfona intratecais tendo estabi-lidade melhorada
MX374220B (es) Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados.
EA201690327A1 (ru) Терапевтические способы
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
BR112014000889A2 (pt) tratamento para hipoxia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]